Wednesday, 23 January 2019

Dry Eye Syndrome Market Growth and Restrain Factors Analysis By 2023

Market Synopsis
Tears provide lubrication, limits the risks of eye infections, washes away the foreign matter, thus, are helpful in keeping the surface of the eyes smooth and clear. Dry eye syndrome is a medical condition in which eyes’ lubrication is hindered by the unavailability of tears. Under normal condition, during excessive production, tears flow into the small drainage ducts of the inner corners of the eyes, followed by draining back into the nose. Sometimes when the production of tears and drainage is not balanced, it can result into dry eye syndrome. Eye redness, sensitivity to light, watery eyes, eye fatigue are some of the common symptoms of the disease. Increasing geriatric population, rising prevalence of diseases like diabetes, rheumatoid arthritis, and others are estimated to be the major drivers for the market growth.
According to the World Health Organization in 2016, approximately 422 million adults were globally affected by diabetes in 2014, as compared to 108 million in the 1980’s. Moreover, in 2014, it was estimated that the global prevalence of diabetes was estimated to be around 8.5%. Additionally, rising per capita healthcare expenditure, and changing lifestyle boosts the market. However, factors like stringent FDA drug approvals, lack of skilled ophthalmologists, and low per capita healthcare expenditure in the middle and low income countries are restraining the market. 
The market for global dry eye syndrome is expected to advance with an approximate CAGR of 6.6% during the forecast period.
Segmentation
The global dry eye syndrome is segmented on the basis of the type, diagnosis, treatment, distribution channel and end user.
On the basis of the type, the market is segmented into evaporative dry eye syndrome aqueous dry eye syndrome, and others. On the basis of the diagnosis, the market is categorized into Schirmer test, eye exam, and others.  On the basis of the treatment, the market is segmented into nutritional supplements, serum eye drops, lubricant eye drops, anti-inflammatory drugs segments, surgery, and others. The lubricant eye drops segment is sub-segmented into oily tear eye drops, ointments, preservative-free drops, and others. The anti-inflammatory drugs segments segement is sub-segmented into tetracyclines, corticosteroids, and others. The surgery segment is sub-segmented into punctal occlusion, intense pulsed light therapy, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.  On the basis of the end users, the market is segmented into hospitals, clinics, home care, and others.
Key Players
The key players for the global dry eye syndrome are Allergan (Republic of Ireland), Novartis AG (Switzerland), Otsuka Pharmaceutical Co. Ltd. (Japan), Valent Pharmaceuticals (Canada), Johnson & Johnson Vision (U.S.), Acadia Pharmaceutical (U.S.), Allostera Pharma (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT pharmaceuticals (New Zealand), Novaliq GmBh (Germany), Auven therapeutics (U.S.), and others.
Regional Analysis
Asia Pacific is the fastest growing region for the market due to the presence of economies like India, China, Australia, and others. Moreover, huge patient population, rising healthcare expenditure boosts the market growth. According to the Australian Institute of Health and Welfare, the total Australian health expenditure from 2015 to 2016 was estimated to be about USD 170.4 billion.
America dominates the global dry eye syndrome market. This can be attributed to the presence of a well-developed healthcare sector and a large patient population. Moreover, increasing healthcare expenditure boosts the growth of the American market. Additionally, the presence of the major market players like Johnson & Johnson Vision, Auven therapeutics, Acadia Pharmaceutical, and others within the region fuels the market growth.
The Middle East & Africa has the least share in the global dry eye syndrome due to the presence of poor economies, low per capita healthcare expenditure, stringent government policies, especially within the African region. The Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure by the developed economies like Dubai, Kuwait, Dubai, and others.
Europe is the second largest dry eye syndrome market owing to increasing availability of funds for research, a well-developed healthcare sector, huge patient pool and growing geriatric population. According to the Saga in 2017, approximately 20% of people living in the U.K suffer from dry eye syndrome. Moreover, it was estimated that one in three people who age 65 or more within the region are diagnosed with this disease.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/dry-eye-syndrome-market-5588
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Bile Duct Cancer Market - Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2023

Market Scenario:
Intensifying number of bile duct cancer cases being diagnosed globally have fortified the need for cutting-edge solutions in terms of procedure and medicines to treat the condition. Market reports associated with the healthcare sector made accessible by Market Research Future along with published reports on other sectors have been lately put out along with a report on this industry.
The market is anticipated to develop at an increasing CAGR of 9.2 percent in the forecast period.
The mounting level of spending being devoted to research for the treatment of bile duct cancer is positively contributing to increasing the market share globally. This has allowed the development of pioneering procedures to treat this form of cancer apart from the traditional solution involving chemotherapy. Additionally, factors such as growing healthcare expenses and mounting awareness for the disease are projected to boost the progress of the market in the forecast period.
Segmentation
The global bile duct cancer market is segmented on the basis of types, diagnosis, treatment, and end users.
On the basis of types, the market is segmented into intrahepatic, extrahepatic, and others.
On the basis of treatment, the market is segmented into chemotherapy, radiotherapy, and others. The chemotherapy segment is sub segmented into 5-fluorouracil, gemcitabine, cisplatin, and others.
On the basis of diagnosis, the market is segmented into blood tests, abdominal imaging, surgery, and others. The diagnosis segment by abdominal imaging is sub segmented into endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), magnetic resonance cholangiopancreatography (MRCP), and others.
On the basis of end users, the market is segmented into hospital &clinics, academic institutes, research organizations and others.
Key players for Global Bile Duct Cancer Market
The key players for the global bile duct cancer market are Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Europe), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd. (Middle East), Eli Lilly and Company. (U.S.), Sanofi (Europe), Fresenius Kabi AG (Europe), Mylan N.V. (U.S.), and others.
Regional Analysis
The Americas dominates the global bile duct cancer market owing to a well-developed healthcare sector. Apart from this, increasing number of patients, increasing healthcare expenditure have boosted the growth of the market in the Americas. According to the Centers for Disease Control and Prevention, U.S. health care spending in 2015, reached $3.2 trillion or $9,990 per person which accounted for 17.8% of the total GDP.
Europe is the second largest bile duct cancer market, which is followed by Asia Pacific. Availability of funds for research, huge patient population and government support for research & development drives the European market.
Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies like India and China, and presence of huge opportunity in the market. According to Indian Brand Equity Fund, the per capita healthcare expenditure in India is estimated to grow at a CAGR of 5% during 2008-15 and reach USD 68.6 by 2015.
Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/bile-duct-cancer-market-4741
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Aphakia Market Revenue, Opportunity, Forecast and Value Chain 2018

Market Scenario
Aphakia is the absence or dislocation of lenses. Increasing prevalence of diabetes & other diseases, rising demand for the better treatment, and increasing number of ophthalmic surgeries drives the growth of the market. According to World Health Organization, in 2014, 285 million people were visually impaired across the globe and about 24.4 million American aged over 40 and half of the people who are over 75 have cataracts problem. Furthermore, in 2014, glaucoma affected over 2.7 million Americans of age 40 and older. Changing lifestyle and increasing geriatric population have increased the probability of causing aphakia. Additionally, increasing need for the cost-effective treatment and increasing per capita income have fuelled the market growth. However, limited treatment options and high cost of the surgery may affect the growth of the market over the assessment period, negatively.
The global aphakia market is expected to grow at a CAGR of ~ 9.2% during the forecast period 2017-2023.
Key Players
  • Johnson & Johnson Services, Inc. (US),
  • Ophtec BV (Netherland),
  • Alcon Laboratories, Inc. (Switzerland‎),
  • Bausch & Lomb (US),
  • Carl Zeiss AG (Germany),
  • Rayner Company (US),
  • Bohus BioTech AB (Sweden),
  • CooperVision, Inc. (US),
  • Lifecore Biomedical, LLC (US),
  • Aetna Inc. (US),
  • Ciba Vision (Switzerland),
  • Menicon (Singapore).

Segmentations
The global aphakia market has been segmented on the basis of types, causes, treatment, and end user.
On the basis of type, the market is segmented into primary, and secondary.
On the basis of cause, the market is categorized into congenital aphakia, surgical aphakia, acquired aphakia, and others. Acquired aphakia is further segmented into traumatic extrusion, posterior dislocation, couching, and other.
On the basis of treatment, the market is segmented into spectacles, contact lenses, intraocular lens implantation, refractive surgery, and others. The spectacles are sub-segmented into +10D, +3-4D, and other. Refractive surgery is further segmented into keratophakia, epikeratophakia, and hyperopic LASIK.
On the basis of end user, the market is segmented into hospitals, ophthalmic clinics, and others.
Regional Analysis
The Worldwide Aphakia Market is segmented on the basis of types, causes, treatment, and end user. On the basis of type, the market is segmented into primary and secondary. On the basis of cause, the market is categorized into congenital aphakia, surgical aphakia, acquired aphakia and others. The acquired aphakia is further segmented into traumatic extrusion, posterior dislocation, couching, and other. Aphakia is the absence or dislocation of lenses.
The Americas dominates the global aphakia market owing to the increasing prevalence of people with aphakia. It was estimated that 6.1 million (5.1%) of Americans have pseudophakia/aphakia. Additionally, well-developed technology, huge diabetic population, and strong government support for research & development will fuel the market growth.
Europe is the second leading market across the globe, which is followed by Asia Pacific. Availability of funds for research, huge geriatric population and government support for research & development will drive the market.
Asia Pacific is the fastest growing aphakia market due to the presence of rapidly growing economy, huge patient pool, increasing prevalence of ophthalmic diseases, and presence of huge geriatric population.
On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited availability of medical facilities, and poor political conditions in Africa.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/aphakia-market-4349


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Peptic Ulcer Drugs Market Growth and Restrain Factors Analysis By 2023

Market Scenario
Peptic ulcer drugs are used to treat erosion of the gastrointestinal lining due to a variety of factors. Peptic ulcer is the result of an imbalance between aggressive and defensive fluids in the stomach. Peptic ulcer includes gastric, esophageal and duodenal ulcer. The global peptic ulcer drugs market was valued at approximately $29 billion in 2015, and is expected to reach $36.27 billion by 2022. Thus, the market is expected to show an average growth at a CAGR of 3.8 % from 2016 to 2022.
The major driving factors for petic ulcers drug market are stress, drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food, rise in cancer, tobacco and alcohol use. Constraining factors of this market are patent expiry, comparatively good treatment regimen of proton pump inhibitors, resistance of H.Pyrolli, extreme market fragmentation into many companies and great penetration of generics.
Key Players For Global Peptic Ulcer Drugs Market:
Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. Helicure AB and Eumedica Pharmaceuticals

Segments:
Global peptic ulcer drugs market has been segmented on the basis of pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer) and region.
Intended Audience:
Global peptic ulcer drugs manufacturers
  • Global peptic ulcer drugs suppliers
  • Research and development Laboratories
  • Market research and consulting service providers

Regional Analysis of Global Peptic Ulcer Drugs Market:
Globally North America is the largest market of global peptic ulcer drugs. Europe is the second largest market for global peptic ulcer drugs. Soon the market of peptic ulcer drugs will be dominated by developing regions particularly Asia Pacific which will be the fastest growing region. 
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/peptic-ulcer-drugs-market-2445



About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Wound Closure Device Market - Granular Market Report and Review, 2018

Market Scenario:
The global wound closure device market is expected to grow during the forecast period (2018 to 2023) at a CAGR ~6.9%.
Wound closure devices are used for closure of the wound by pulling both the edges together. After surgical procedures, incisions and small wounds are created due to medical interventions. Wound closure devices are used for fast recovery and healing of such wounds. Growing volume of surgical procedures is the primary reason behind increasing the demand for wound closure devices. The increase in a number of plastic and cosmetic surgeries, increasing number of burns, trauma, and accidents, and sports-related injuries are expected to drive the growth of the market. The market is highly fragmented and major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.
Moreover, advancement in technology, decrease in a number of surgical site infections and attempts to reduce hospital stays for reducing surgical expenditure is contributing to the growth of the market. According to a survey conducted by the American Professional Wound Care Association (2017), chronic nonhealing wounds impact nearly 15% of Medicare beneficiaries (8.2 million). The estimated spending for primary wound diagnosis is USD 28 billion per year and the cost for secondary wound diagnosis is estimated to be USD 31.7 billion.  
The risk associated with infectious wounds, side effects of wound closure devices, and unfavorable reimbursement policies may hamper the growth of the market during the assessment period.
Key Players
Some of the key players in the global wound closure device market are 3M, Abbott Laboratories, B. Braun Melsungen AG, Ethicon Inc., Medtronic., Smith & Nephew, Baxter International, BSN medical Inc., Derma Sciences, Kinetic Concepts, ConvaTec, DACH Medical Group, Arthrex GmbH, Gecko Biomedical, Integra LifeScience, and CP Medical.
Segmentation
The global wound closure device market has been segmented based on device, application, type of wound, and end-user.
On the basis of device, the market has been classified into adhesives, staples, sutures, and mechanical wound closure devices. Adhesives are furthers classified into fibrin tissue adhesives and cyanoacrylates. The sutures segment has been further divided into absorbable, non- absorbable, braided, and monofilament.
On the basis of application, the market has been classified into burns, ulcers, surgical wounds, pressure ulcers, diabetic ulcers, and arterial ulcers. On the basis of type, the surgical wounds segment has been sub-segmented into chronic wounds, acute wounds, and others.
The market, by end-user, has been segmented into hospitals, community healthcare service providers, ambulatory surgical centers, and home care.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The wound closure device market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European wound closure device market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The wound closure device market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The wound closure device market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas is likely to hold the majority of the global wound closure device market owing to increase in the number of surgical procedures, increasing injuries related to accidents, sports and adventure, aging population, the presence of a well-established healthcare system, and adoption and awareness of the wound closure technology. According to the American Association for the Surgery of Trauma, injury accounts for over 150,000 deaths and over 3 million non-fatal injuries are reported per year in the US.
The European market is expected to be the second-largest wound closure device market after the Americas. The market growth in this region can be attributed to an increase in aged population and rising occurrence of sports injuries and accidents. Moreover, the growing number of road accidents in the European region are contributing to the growth of the market in this region. According to data published by the European Commission in 2018, more than 135,000 people suffered serious injury from road accidents.
Asia-Pacific is expected to be the fastest-growing wound closure device market during the forecast period owing to the significant increase in aged population, increasing prevalence of chronic diseases such as diabetes leading to the increasing cases of diabetic foot ulcer. According to WHO, there are more than 96 million diabetics patients in the Asia-Pacific region.
The market in the Middle East and Africa is expected to account for the smallest share of the global wound closure device market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Browse Complete 90 Pages Premium Research Report Enabled with 92 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/wound-closure-device-market-2001

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Ophthalmic Drugs Market 2018 Share, Trend, Segmentation and Forecast to 2023

Market Scenario
A number of factors such as rising prevalence of eye diseases, growing awareness, huge research funding in ophthalmology, unmet medical needs, rising competition among market players, improving regulatory framework, aging population, and increasing government assistance, are a few factors propelling the growth of the global ophthalmic drugs market.
Ophthalmic diseases are potential threats to the status of sight of the population. Various retinal diseases such as Wet AMD, Diabetic Macular Edema (DME), diabetic retinopathy, Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV) are growing at an alarming rate worldwide.
It is noted that the rising prevalence of eye diseases is the key factor driving the ophthalmic drugs market. According to the 2017 statistics suggested by the World Health Organization (WHO), around 253 million people are living with vision impairment, out of which 36 million are blind and nearly 217 million have moderate to severe vision impairment. It is also reported that the chronic eye disease is the main cause of vision loss, globally. Globally, glaucoma is the second leading cause of blindness, according to the World Health Organization, and blindness due to glaucoma is six to eight times more common in African Americans than Caucasians.
Various other factors such as growing awareness of eye diseases, huge research funding in ophthalmology, unmet medical needs, rising competition among market players, improving regulatory framework, aging population, and increasing government assistance are continuously contributing to the growth of the global ophthalmic drugs market.
Despite these drivers, there are some issues associated with the ophthalmic drugs market. The high cost associated with a diagnosis of eye diseases, side effects of available treatment options, lack of healthcare insurance, and poor healthcare system in low and middle-income countries may hamper the growth of the market to an extent.
It is estimated that the ophthalmic drugs market is expected to grow at a CAGR 6.0% during the forecast period of 2017–2023.
Segmentation
The global ophthalmic drugs market is segmented on the basis of indication, drug class, type of dosage, product, and distribution channel.
On the basis of indication, the market is classified as glaucoma, retinal disorders, inflammation/infection, dry eye, allergies, uveitis, and others.
On the basis of drug class, the market is classified as antiallergy, anti-VEGF agents, anti-inflammatory, antiglaucoma, and others. The anti-inflammatory segment is further segmented into nonsteroidal drugs and steroidal drugs.
On the basis of type of dosage, the market is classified as eye drops, eye solutions, ointments, capsules and tablets, and gels.
On the basis of the product, the market is classified as prescription drugs and OTC drugs.
On the basis of the distribution channel, the market is classified as hospital pharmacies, online pharmacies, drug stores, and others.
Regional Analysis
The Americas dominates the ophthalmic drugs market owing to the presence of patient population, rising prevalence of eye diseases, well-developed technology, high healthcare expenditure, and the presence of the leading players. According to the glaucoma research foundation, in the United States, more than 120,000 are blind because of glaucoma. This accounts for 9 to 12% of all cases of blindness. It is also reported that over 3 million Americans have glaucoma, but only a few of them know they have it. It is also reported that glaucoma accounts for more than 10 million visits to physicians each year. In November 2017, Bausch & Lomb, a U.S.-based company, received the FDA approval for Vyzulta (latanoprostene bunod ophthalmic solution). The drug is designed for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. In December 2017, Rhopressa (netarsudil ophthalmic solution) by Aerie Pharmaceuticals has also received FDA approval for the treatment of glaucoma or ocular hypertension.
Europe holds the second position in the ophthalmic drugs market. It is expected that the government support towards research and development expenditure, increasing competition among marketers, and amendments in reimbursement policies in healthcare are likely to drive the European market.
Asia Pacific is the fastest growing ophthalmic drugs market owing to a huge patient pool, increasing demand, and development of the healthcare technology.
The Middle East and Africa hold the lowest share of the global ophthalmic drugs market due to low development, lack of technical knowledge, and poor medical facilities.
Key Players
Some of the key players in the global ophthalmic drugs market are Actavis Generics, Allergan Plc, Bausch & Lomb Inc., Genentech, Inc., Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Shire Plc, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., and others.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/ophthalmic-drugs-market-5753

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Picture Archiving and Communications Systems Market Anticipated To Witness Noteworthy Growth in the Coming Years

Market Scenario:
Picture Archiving and Communication System (PACS) is a modality of the medical imaging technology used specifically for image transmission from the site of image acquisition to other locations. The technology is convenient to access multiple modalities such as radiographs, CT scan, MRI, ultrasound, and others.
The increasing prevalence of chronic diseases and the growing geriatric population are the key factors driving the Picture Archiving and Communication System (PACS) market. The increasing burden of chronic diseases has been observed in different parts of the world. Population in the low socio-economic group is mostly found to get affected by these chronic diseases. According to the report published in the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults are dealing with at least one type of cardiovascular disease. The prevalence of type-2 diabetes, obesity, and cardiovascular diseases has increased rapidly in the recent years, suggested by a study published in the BMC Public Health in 2017.
Various other factors such as supportive investments and funds provided by government and private bodies, rising demand for early diagnosis, technological advancements in the medical imaging devices, rising incidence of cancer, improving regulatory framework, growing research funding, unmet medical needs, rising competition among market players, and increasing government assistance are continuously contributing to the growth of the global PACS market.
Despite these drivers, there are some issues associated with the PACS market. The high cost associated with the technology, lack of healthcare insurance, lack of awareness, and poor healthcare system in low- and middle-income countries may hamper the growth of the market.
It is estimated that the Picture Archiving and Communications Systems (PACS) market is expected to grow at a CAGR 7.0% during the forecast period of 2017–2023.
Segmentation
The global Picture Archiving and Communications Systems (PACS) market is segmented on the basis of type, component, imaging type, delivery mode, and end-user.
On the basis of type, the market is classified as oncology PACS, cardiology PACS, dental PACS, orthopedics PACS, and others.
On the basis of components, the market is classified as hardware, software, and services. The hardware segment is further classified as access devices, peripherals, servers, storage devices, and networking devices. The services segment is further classified as consulting, implementation services, post-sales and maintenance services, and training services.
On the basis of the type of imaging type, the market is classified as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), nuclear imaging, X-ray, and ultrasound.
On the basis of end-user, the market is classified as hospitals and clinics, healthcare centers, imaging centers, diagnostic centers, clinical research institutions, and others.
On the basis of delivery mode, the market is classified as cloud-based (SAAS) delivery mode, web-hosted (On-Demand) delivery mode, and on-premise mode.
Regional Analysis
Radiology imaging solutions have generated a significant return on its healthcare IT investment by implementing Exa’s Voice Recognition in place of traditional transcriptionists, and their productivity has increased by 400%.           
The Americas dominates the Picture Archiving and Communications Systems (PACS) market owing to the rising demand for early diagnosis, rising prevalence of chronic diseases, well-developed technology, high healthcare expenditure, and the presence of leading players. Owing to the rising demand for imaging devices, various market players are coming up with advanced technology. For instance, on March 26, 2018, Singular Medical Technologies (SMT), the U.S. based technology company announced two new additions to its PACStation suite of products. The PACStation-GO is a fully functional reading workstation, with two full-size diagnostic monitors and is completely portable.
Europe holds the second position in the Picture Archiving and Communications Systems (PACS) market. It is expected that the funding towards research and development expenditure and increasing competition among marketers are likely to drive the European market.
Asia Pacific is the fastest growing Picture Archiving and Communications Systems (PACS) market owing to a huge patient pool, increasing demand for diagnosis, and development in the healthcare IT sector. According to IBEF, the Healthcare Information Technology (IT) market was valued at USD 1 billion in 2016 which is estimated to grow 1.5 times by 2020.
The Middle East and Africa holds the lowest share of the global Picture Archiving and Communications Systems (PACS) market due to low development, lack of technical knowledge, and poor medical facilities.
Key Players
Some of the key players in the global Picture Archiving and Communications Systems (PACS) market are Advanced Data Systems, Agfa-Gevaert N.V., Allscripts Healthcare Solutions, Inc., ALTA VISTA TELERADIOLOGY, Argus Radiology, Avreo, Inc., Brit Systems, Comarch SA, Cybernet Medical Corporation, FujiFilm Medical Systems, GE Healthcare, Global Diagnostics, INFINITT Healthcare, Konica Minolta Healthcare Americas Inc., McKesson Corporation,Inc., ONRAD, Inc., Pacshealth, LLC, PERFECT IMAGING, LLC, RamSoft, Inc., Radiology Imaging Solutions, Scimage, Inc., Sectra Imtec AB, Sectra Imtec AB, Siemens Healthineers, Singular Medical Technologies, StatRad, LLC, Telediagnostics Services Pvt. Ltd., Telerad Tech Private Limited, Virtual Radiology (vRAD), and others
Browse Complete 100 Pages Premium Research Report Enabled with 87 Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/picture-archiving-communications-systems-market-5833
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com